- Home
- SOPH vs INBX Comparison
SOPH vs INBX Comparison
Compare SOPH & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOPH
- INBX
- Stock Information
- Founded
- SOPH 2011
- INBX 2010
- Country
- SOPH Switzerland
- INBX United States
- Employees
- SOPH N/A
- INBX N/A
- Industry
- SOPH Biotechnology: Biological Products (No Diagnostic Substances)
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- SOPH Health Care
- INBX Health Care
- Exchange
- SOPH Nasdaq
- INBX Nasdaq
- Market Cap
- SOPH 247.0M
- INBX 237.5M
- IPO Year
- SOPH 2021
- INBX 2020
- Fundamental
- Price
- SOPH $3.50
- INBX $15.74
- Analyst Decision
- SOPH Strong Buy
- INBX Hold
- Analyst Count
- SOPH 3
- INBX 1
- Target Price
- SOPH $7.00
- INBX N/A
- AVG Volume (30 Days)
- SOPH 28.9K
- INBX 104.9K
- Earning Date
- SOPH 11-05-2024
- INBX 08-13-2024
- Dividend Yield
- SOPH N/A
- INBX N/A
- EPS Growth
- SOPH N/A
- INBX N/A
- EPS
- SOPH N/A
- INBX 118.83
- Revenue
- SOPH $64,938,000.00
- INBX $1,687,000.00
- Revenue This Year
- SOPH $7.70
- INBX N/A
- Revenue Next Year
- SOPH $20.61
- INBX N/A
- P/E Ratio
- SOPH N/A
- INBX $0.13
- Revenue Growth
- SOPH 20.14
- INBX 24.26
- 52 Week Low
- SOPH $2.70
- INBX $10.80
- 52 Week High
- SOPH $7.37
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- SOPH 42.10
- INBX 53.98
- Support Level
- SOPH $3.30
- INBX $15.31
- Resistance Level
- SOPH $3.54
- INBX $16.35
- Average True Range (ATR)
- SOPH 0.21
- INBX 0.58
- MACD
- SOPH -0.02
- INBX -0.05
- Stochastic Oscillator
- SOPH 34.00
- INBX 63.69
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.